Efficacy of GnRH-a in combination with dienogest therapy in endometriosis and its effects in recurrence and pregnancy status

Group	Cumulative pregnancy rate	Live birth rate	Miscarriage rate	Multiple pregnancy rate	Ectopic pregnancy rate
DT group	26 (20.47)	22 (17.32)	4 (3.15)	0 (0.00)	2 (1.57)
GD group	48 (37.80)	42 (33.07)	2 (1.57)	0 (0.00)	0 (0.00)
x²	7.868	6.827	0.205	-	2.020
P	<0.05	<0.05	0.651	-	0.155

	DT group	GD group	t	P	Effect size
Pre-treatment	13.18 ± 1.94	13.10 ± 2.18	−0.309	0.758	0.039
Post-treatment	9.47 ± 1.50	7.58 ± 1.38	−10.450	<0.001	1.311
t	−17.049	−24.111
P	<0.001	<0.001
Effect size	2.140	3.026

Norm	Time	DT group	GD group	t	P	Effect size
CRP	Pre-treatment	6.20 ± 0.38	6.21 ± 0.39	0.207	0.836	−0.026
	Post-treatment	4.03 ± 0.39^*	3.25 ± 0.38^*	−16.143	<0.001	2.026
TNF-α	Pre-treatment	5.07 ± 0.50	5.01 ± 0.48	−0.976	0.330	0.122
	Post-treatment	2.39 ± 0.30^*	1.61 ± 0.29^*	−21.067	<0.001	2.644
IL-6	Pre-treatment	16.06 ± 2.21	15.78 ± 2.70	−0.904	0.367	0.113
	Post-treatment	12.39 ± 1.66^*	6.58 ± 1.67^*	−27.807	<0.001	3.489

	DT group	GD group	x²	P
Nausea/vomiting	4 (3.15)	3 (2.36)	0.205	0.651
Hot flashes/sweating	1 (0.79)	0 (0.00)	1.005	0.316
Headache	2 (1.57)	1 (0.79)	0.338	0.561
Diarrhea	4 (3.15)	1 (0.79)	1.020	0.312
Vaginal bleeding	2 (1.57)	0 (0.00)	2.020	0.155
Pelvic inflammatory disease	2 (1.57)	0 (0.00)	2.020	0.155
Ovarian hyperstimulation syndrome	1 (0.79)	2 (1.57)	0.338	0.561
Urinary tract infection	2 (1.57)	0 (0.00)	2.020	0.155
Osteoporosis	1 (0.79)	0 (0.00)	1.005	0.316
Total response incidence	19 (14.96)	7 (5.51)	4.310	<0.05

Norm	Time	DT group	GD group	t	P	Effect size
FSH (U/L)	Pre-treatment	5.78 ± 1.34	5.84 ± 1.56	0.329	0.743	−0.041
	Post-treatment	4.03 ± 1.22^*	3.22 ± 1.39^*	−4.936	<0.001	0.619
LH (U/L)	Pre-treatment	6.42 ± 1.46	6.51 ± 1.38	0.505	0.614	−0.063
	Post-treatment	5.46 ± 1.21^*	4.21 ± 1.03^*	−8.865	<0.001	1.112
E2 (pg/mL)	Pre-treatment	72.82 ± 13.37	72.52 ± 15.96	−0.162	0.871	0.020
	Post-treatment	61.83 ± 12.91^*	50.22 ± 10.06^*	−7.994	<0.001	1.003

Group	Obvious effect (n)	Effective (n)	Ineffective (n)	Total effective rate n (%)
DT group	50	52	25	102 (80.31)
GD group	58	60	9	118 (92.91)
x²	7.236
P	<0.05

Norm	Time	DT group	GD group	x²	P
AEmAb	Pre-treatment	38 (29.92)	37 (29.13)	0.024	0.877
	Post-treatment	22 (17.32)^*	9 (7.09)^*	4.735	<0.05
AsAb	Pre-treatment	39 (30.71)	40 (31.50)	0.011	0.917
	Post-treatment	22 (17.32)^*	8 (6.30)^*	5.944	<0.05
AZpAb	Pre-treatment	41 (32.28)	42 (33.07)	0.023	0.880
	Post-treatment	23 (18.11)^*	9 (7.09)^*	5.531	<0.05

Parameter	DT group (n = 127)	GD group (n = 127)	t/x²	P	Effect size
Age (years)	33.13 ± 7.46	34.78 ± 8.53	1.641	0.102	−0.206
Infertility time (years)	24.59 ± 8.58	24.51 ± 8.43	−0.075	0.940	0.009
Height (years)	159.60 ± 5.20	158.67 ± 5.15	−1.432	0.153	0.180
Weight (kg)	64.75 ± 7.72	64.33 ± 7.06	−0.452	0.651	0.057
Body mass index (kg/m²)	23.42 ± 2.95	22.99 ± 2.52	−1.249	0.213	0.157
Ovarian cysts (single/double)	89/38	83/44	0.648	0.421
Smoking (yes/no)	10/117	9/118	0.057	0.811
Alcohol consumption (yes/no)	15/112	13/114	0.161	0.689
Hypertension (yes/no)	23/104	25/102	0.103	0.749
Diabetes (yes/no)	26/101	27/100	0.024	0.877
Autoimmune disease (yes/no)	5/122	4/123	0.115	0.734
Uterine fibroid tumor (yes/no)	40/87	38/89	0.074	0.786
Cesarean section (yes/no)	48/79	46/81	0.068	0.795
History of gynecologic surgery (yes/no)	10/117	11/116	0.052	0.820
Temperature (°C)	36.37 ± 0.29	36.42 ± 0.30	1.350	0.178	0.169
Breathing (breaths/min)	17.05 ± 1.80	17.12 ± 1.85	0.306	0.760	−0.038
Heart rate (beat/min)	75.34 ± 7.15	74.79 ± 7.17	−0.612	0.541	0.077
Systolic blood pressure (mmHg)	119.52 ± 6.25	119.26 ± 6.14	−0.334	0.738	0.042
Diastolic blood pressure (mmHg)	75.91 ± 6.18	76.31 ± 5.75	0.534	0.594	−0.067